Rossari Biotech Q2 FY26 Results: Revenue Increases 18% YoY to ₹586.1 Crore, Profit Increases 5%

Mumbai, October 16, 2025 – Rossari Biotech Limited (NSE: ROSSARI, BSE: 543213) announced a robust performance of financial results for the quarter ended and half-year ended September 30, 2025, driven by strong volume growth in all business segments.

Q2 FY26 Financial Performance

Rossari Biotech recorded operating revenue of ₹586.1 crore, higher by 18% YoY from ₹498.4 crore in Q2 FY25. EBITDA increased 9% YoY to ₹71.9 crore, at an EBITDA margin of 12.3%. Profit after tax (PAT) rose 5% YoY to ₹36.9 crore, with diluted EPS of ₹6.7 for the quarter.

H1 FY26 Performance Overview

For H1 FY26, the firm recorded revenue of ₹1,129.8 crore, up by 14% YoY, with EBITDA growth of 7% to ₹139.7 crore, at a margin of 12.4%. PAT for H1 FY26 was ₹70.5 crore, relatively unchanged from ₹70.2 crore in H1 FY25, with EPS at ₹12.7.

Segment and Export Growth

The company registered pan-vertex growth in its major verticals in Q2 FY26:

• Home, Personal & Performance Chemicals (HPPC): +16% YoY
• Textile Specialty Chemicals (TSC): +21% YoY
• Animal Health & Nutrition (AHN): +29% YoY

Exports continued to grow robustly, increasing 36% YoY in Q2 and 27% in H1, accounting for close to 28% of sales, supported by greater customer interaction and new market penetration.

Management Commentary

Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said:

“We achieved healthy revenue growth of 18% year-on-year in Q2 FY26, with robust volume growth across our diversified portfolio. Though influenced by muted pricing and expenditure on new business opportunities, profitability was stable. Progress in our exports and capacity additions is on track, poised to harness emerging opportunities worldwide.”

Key Strategic Developments

Dahej Expansion: Commissioned incremental 20,000 MTPA capacity, increasing total installed capacity to 1,52,500 MTPA.

Unitop Expansion: Installed an additional 15,000 MTPA ethoxylation capacity (Phase 1 of a 30,000 MTPA project), with the second phase due in Q3 FY26.

Global Expansion: Authorized up to USD 8 million investment in tranches in its Saudi Arabia subsidiary, Rossari International Limited Company (RILC), for global capacity assessment and development of markets.

With headquarters in Mumbai, Rossari Biotech Limited is a specialty chemical company with sustainable and smart solutions for Home, Personal Care & Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health & Nutrition (AHN). Rossari Biotech Limited has manufacturing facilities at Silvassa and Dahej with strong distribution networks both domestically in India and internationally.

Rossari further capitalizes on its diversified product basket and export growth to bolster its foothold in the international specialty chemicals industry.

REF: https://nsearchives.nseindia.com/corporate/ROSSARI_16102025164505_20251016_Intimation_of_Press_Release_Q2_FY26.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations